BioLife Solutions BLFS Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Noncurrent
Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Noncurrent at other companies
Other financials
Where this comes from
Reported directly by BioLife Solutions in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent.
The official record: BioLife Solutions’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioLife Solutions's debt securities available for sale accrued interest after allowance for credit loss noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioLife Solutions's debt securities available for sale accrued interest after allowance for credit loss noncurrent?
- BioLife Solutions (BLFS) reported debt securities available for sale accrued interest after allowance for credit loss noncurrent of $30.5M in Q1 2026.
- How has BioLife Solutions's debt securities available for sale accrued interest after allowance for credit loss noncurrent changed year-over-year?
- BioLife Solutions's debt securities available for sale accrued interest after allowance for credit loss noncurrent increased by 60.1% year-over-year, from $19.06M to $30.5M.
- What does debt securities available for sale accrued interest after allowance for credit loss noncurrent mean?
- This represents the portion of long-term debt security investments held by the company that are classified as available for sale, net of any expected credit losses. It reflects the value of interest-bearing assets intended to be held beyond one year, providing insight into the company's long-term liquidity management and investment strategy. Monitoring this balance helps investors assess the risk profile and potential yield generation of the company's non-operating asset portfolio.